Accelerating Radiopharmaceutical Development in Oncology
Crown Bioscience and Medicines Discovery Catapult (MDC) partner to streamline workflows for radiopharmaceuticals, bridging radiochemistry, pharmacology, and translational science.
What are Radiopharmaceuticals?
Radiopharmaceuticals are targeted therapeutics that combine a biologically active molecule (peptide, antibody, or small molecule) with a radioactive isotope (alpha or beta emitter).
They deliver localized radiation to tumor cells with high precision while sparing healthy tissue. Applications span diagnostic imaging (PET, SPECT) and therapeutics (Lu-177, Ac-225, Pb-212).
Crown Bioscience + MDC Partnership
Crown Bioscience and Medicines Discovery Catapult are delighted to announce a strategic partnership aimed at revolutionizing radiopharmaceuticals for cancer treatment.
Efficacy Testing
Predictive CDX, PDX and Orthotopic Models
CDX for early screening, PDX for late-stage efficacy, orthotopic models for complexity. PDXs retain the microenvironment and stroma, making them highly predictive. All models reflect clinical diversity and are accepted by regulators and investors alike.
Radiochemistry
Isotope Expertise
MDC offers flexible radiolabelling for alpha- and beta-emitting isotopes, including Ac-225, Lu-177, and Pb-212. Their experience spans antibodies, peptides, and other therapeutic formats, guiding clients in isotope and chelator selection.
Imaging and Biodistribution
High-Sensitivity Visualization
Precise gamma counting uses a “cut and count” method, quantifying radioactivity in excised tumors and organs. This provides clients with detailed data on compound localization, off-target retention, and clearance rates.
Comparator Studies
Regulatory Confidence With Comparators
The collaboration enables preclinical comparator studies with approved standards of care, such as Pluvicto (Lu-177-PSMA) or external beam radiation therapy (EBRT), supporting clients preparing for IND submissions.
Frequently Asked Questions
Learn how Crown Bioscience and MDC are advancing radiopharmaceutical development.
How is the collaboration accelerating radiopharmaceutical development?
By integrating advanced imaging and validated model systems, we rapidly assess the targeting efficiency, biodistribution, and therapeutic potential of radiopharmaceutical candidates.
How is targeted radionuclide development being advanced?
The collaboration accelerates the development of targeted alpha- and beta-emitting radionuclides, improving radiation precision to tumor cells while reducing off-target toxicity.
Why does this collaboration matter?
Radiopharmaceuticals are emerging as a major pillar in cancer treatment. Crown Bioscience and MDC streamline workflows, generate translational data, and support precision medicine strategies that directly impact patient outcomes.
